6533b83afe1ef96bd12a7c31

RESEARCH PRODUCT

Adjuvant denosumab in early breast-cancer

Giuseppina CampisiAlberto BedogniVittorio Fusco

subject

Oncologymedicine.medical_specialtyadjuvant denosumab early-stage breast cancerBone Density Conservation AgentsAromatase Inhibitorsbusiness.industrymedicine.medical_treatmentMEDLINEantiresorptives denosumab breast cancer osteonecrosis od the jawosteonecrosis od the jawdenosumabantiresorptivesBone Density Conservation Agentsbreast cancerDenosumabOncologyInternal medicineMedicinebusinessAdjuvantmedicine.drugEarly breast cancer

description

We read with interest the D-CARE trial report by Robert Coleman and colleagues1 on the adjuvant administration of denosumab in patients with early-stage breast cancer. Despite the negative results, which pose concerns about high dose denosumab schedules in an adjuvant setting, this large and well- designed trial can provide useful clinical data that are usually difficult to obtain from observational studies, particularly regarding medication- related osteonecrosis of the jaw (MRONJ).

yearjournalcountryeditionlanguage
2020-01-01The Lancet Oncology
https://doi.org/10.1016/s1470-2045(20)30066-8